Bronchial Spasm Market Report 2026

Bronchial Spasm Market Overview

• Bronchial Spasm market size has reached to $3.82 billion in 2025 • Expected to grow to $5.35 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Respiratory Disease Prevalence Driving The Market Growth Due To Increasing Air Pollution And Chronic Respiratory Conditions • Market Trend: Advancements In Combination Therapies Enhancing Symptom Relief And Reducing Severe Respiratory Episodes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bronchial Spasm Market?

Bronchial spasm refers to the sudden and involuntary contraction of the smooth muscles surrounding the bronchial airways, which leads to significant narrowing of the air passages, increased airway resistance, and reduced airflow to the lungs. This condition results in symptoms such as wheezing, chest tightness, persistent coughing, and shortness of breath and is commonly associated with asthma, allergic reactions, respiratory infections, and chronic obstructive pulmonary disease. The main drug types of bronchial spasm include Bronchodilators, anti-inflammatory agents, and combination therapies. Bronchodilators refer to drugs that relax the bronchial muscles to improve airflow and relieve bronchospasm. These treatments are administered via inhalation, oral, or injectable routes. They are used for diagnosis types such as imaging tests, spirometry tests, and other diagnosis types. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, and the end users are hospitals, specialty clinics, and homecare settings.

What Is The Bronchial Spasm Market Growth Forecast?

The bronchial spasm market size is expected to see strong growth in the next few years. It will grow to $5.35 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory therapies, rising integration of digital inhaler monitoring, expansion of homecare respiratory management, growing focus on preventive pulmonary care, increasing development of novel bronchodilator formulations. Major trends in the forecast period include increasing adoption of combination inhaler therapies, rising demand for fast-acting rescue medications, growing use of smart inhaler devices, expansion of home-based respiratory care solutions, enhanced focus on personalized respiratory treatment.

Global Bronchial Spasm Market Segmentation

1) By Drug Type: Bronchodilators; Anti Inflammatory Agents; Combination Therapies 2) By Route Of Administration: Inhalation; Oral; Injectable 3) By Diagnosis Type: Imaging Test; Spirometry Test; Other Diagnosis Types 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies 5) By End User: Hospitals; Specialty Clinics; Homecare Settings Subsegments: 1) By Bronchodilators: Short Acting Beta Agonists; Long Acting Beta Agonists; Anticholinergic Agents; Methylxanthine Agents 2) By Anti Inflammatory Agents: Corticosteroid Agents; Leukotriene Modifier Agents; Mast Cell Stabilizer Agents; Nonsteroidal Anti Inflammatory Agents 3) By Combination Therapies: Beta Agonist And Corticosteroid Combinations; Anticholinergic And Beta Agonist Combinations; Anti Inflammatory And Bronchodilator Combinations; Dual Mechanism Respiratory Combinations

What Is The Driver Of The Bronchial Spasm Market?

The rising prevalence of respiratory diseases is expected to propel the growth of the bronchial spasm market going forward. Respiratory diseases are disorders that affect the respiratory system, leading to difficulty in breathing and reduced oxygen supply to the body. Respiratory diseases are increasing due to rising air pollution levels that elevate long-term exposure to harmful particulate matter and pollutants. Bronchial spasm helps identify and explain respiratory diseases by highlighting the airway muscle constriction that causes breathing difficulty and serves as a key clinical indicator of conditions such as asthma and chronic obstructive pulmonary disease. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the number of COPD cases was expected to rise by 112 million, reaching a total of 592 million by 2050, which would represent 9.5% of the eligible population. Therefore, the rising prevalence of respiratory diseases is driving the growth of the bronchial spasm industry.

Key Players In The Global Bronchial Spasm Market

Major companies operating in the bronchial spasm market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Viatris Inc., Menarini Group, Sandoz AG, Chiesi Farmaceutici S.p.A., Cipla Ltd., Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Amphastar Pharmaceuticals Inc., Nephron Pharmaceuticals Corporation, Beximco Pharmaceuticals Ltd., Circassia Group, Sunovion Pharmaceuticals Inc., PARI Medical Holding GmbH.

Global Bronchial Spasm Market Trends and Insights

Major companies operating in the bronchial spasm market are focusing on developing innovative solutions, such as rescue combination inhalers, to provide rapid symptom relief while simultaneously controlling underlying airway inflammation, improving patient outcomes, and improving adherence. A rescue combination inhaler is an inhaler that delivers both a fast-acting bronchodilator for immediate symptom relief and an anti-inflammatory drug to manage underlying airway inflammation. For instance, in January 2024, AstraZeneca plc, a US-based biopharmaceutical company, received approval from the FDA for AIRSUPRA (albuterol or budesonide), an anti-inflammatory rescue inhaler for asthma in adults aged 18 and older. The therapy provides rapid relief from bronchial spasms, reduces the risk of acute exacerbations, and aligns with updated asthma management guidelines recommending combined symptom and inflammation control. Clinical trial data demonstrated that patients using this approach experienced faster bronchodilation, reduced frequency of severe respiratory episodes, and improved overall disease management, supporting better outcomes for individuals with chronic airway conditions.

What Are Latest Mergers And Acquisitions In The Bronchial Spasm Market?

In October 2025, Merck & Co. Inc., a US-based pharmaceutical company, acquired Verona Pharma plc for an undisclosed amount. Through this acquisition, Merck aims to strengthen its respiratory treatment portfolio by gaining access to Verona’s inhaled chronic obstructive pulmonary disease medication, Ohtuvayre, which helps manage airway constriction and bronchial spasms in adults. Verona Pharma plc is a UK-based company that develops therapies for respiratory diseases, including COPD and asthma-related airway conditions.

Regional Insights

North America was the largest region in the bronchial spasm market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Bronchial Spasm Market?

The bronchial spasm market consists of sales of bronchodilator inhalers, nebulizer solutions, oral bronchodilator tablets, corticosteroid inhalers, combination inhalers, anticholinergic inhalers, rescue inhalers, dry powder inhalers, metered dose inhalers, and inhalation accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bronchial Spasm Market Report 2026?

The bronchial spasm market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bronchial spasm industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.